P844: Frequency and effectiveness of dose de-escalation of biologic therapy in Inflammatory Bowel Disease: The RAINBOW-IBD study of ENEIDAECCO'24Year: 2024
Authors: Rubín De Célix, C.(1)*;Ricart, E.(2);Martín-Arranz, M.D.(3);de Francisco, R.(4);Barrio, J.(5);Mesonero, F.(6);Gomollón, F.(7);de Castro, L.(8);Ramos, L.(9);García-López, S.(10);Arias, L.(11);Mañosa, M.(12);Iglesias, E.(13);Calvet, X.(14);Pascual, I.(15);Casanova, M.J.(1);Pérez-Calle, J.L.(16);Giordano, A.(17);Sierra, M.(18);Vera, I.(19);Navarro-Llavat, M.(20);Lorente, R.(21);Piqueras, M.(22);Rivero, M.(23);Guardiola, J.(24);Esteve, M.(25);Fuentes Coronel, A.(26);Rodríguez-Lago, I.(27);Ponferrada, Á.(28);Ber, Y.(29);Tardillo, C.(30);Márquez, L.(31);Carpio, D.(32);Taxonera, C.(33);Bermejo, F.(34);Busquets, D.(35);Camps, B.(36);Domènech, E.(12);Chaparro*, M.(1);P. Gisbert*, J.(1);
(1)Gastroenterology Department, Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP- Universidad Autónoma de Madrid UAM- and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Madrid, Spain;(2)Gastroenterology Department, Hospital Clínic i Provincial- Institut d’Investigacions Biomèdiques August Pi i Sunyer IDIBAPS- and CIBEREHD, Barcelona, Spain;(3)Gastroenterology Department, Hospital Universitario de La Paz, Madrid, Spain;(4)Gastroenterology Department, Hospital Universitario Central de Asturias and ISPA, Asturias, Spain;(5)Gastroenterology Department, Hospital Río Hortega, Valladolid, Spain;(6)Gastroenterology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain;(7)Gastroenterology Department, Hospital Clínico Lozano Blesa- Instituto de investigación sanitaria de Aragón IIS and CIBEREHD, Zaragoza, Spain;(8)Gastroenterology Department, Hospital Álvaro Cunqueiro, Vigo, Spain;(9)Gastroenterology Department, Complejo Hospitalario Universitario de Canarias, La Laguna, Spain;(10)Gastroenterology Department, Hospital Universitario Miguel Servet and IIS, Zaragoza, Spain;(11)Gastroenterology Department, Hospital Universitario de Burgos, Burgos, Spain;(12)Gastroenterology Department, Hospital Universitario Germans Trias i Pujol and CIBEREHD, Badalona, Spain;(13)Gastroenterology Department, Hospital Reina Sofía- IMIBIC and UCO, Córdoba, Spain;(14)Gastroenterology Department, Hospital Universitari Parc Taulí. Institut d@E@Investigació i Innovació Parc Taulí. Departament de Medicina. Universitat Autònoma de Barcelona and CIBEREHD, Barcelona, Spain;(15)Gastroenterology Department, Hospital Clínico de Valencia, Valencia, Spain;(16)Gastroenterology Department, Hospital Universitario de Alcorcón, Madrid, Spain;(17)Gastroenterology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;(18)Gastroenterology Department, Complejo Asistencial Universitario de León, León, Spain;(19)Gastroenterology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain;(20)Gastroenterology Department, Hospital Moisès Broggi, Sant Joan Despí, Spain;(21)Gastroenterology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain;(22)Gastroenterology Department, Consorci Sanitari de Terrassa, Terrassa, Spain;(23)Gastroenterology Department, Hospital Universitario Marqués de Valdecilla and IDIVAL, Santander, Spain;(24)Gastroenterology Department, Hospital Universitari Bellvitge, L@E@Hospitalet de Llobregat, Spain;(25)Gastroenterology Department, Hospital Universitari Mútua Terrassa. University of Barcelona and CIBEREHD, Terrassa, Spain;(26)Gastroenterology Department, Complejo Asistencial de Zamora, Zamora, Spain;(27)Gastroenterology Department, Hospital de Galdakao, Bilbao, Spain;(28)Gastroenterology Department, Hospital Universitario Infanta Leonor, Madrid, Spain;(29)Gastroenterology Department, Hospital de San Jorge, Huesca, Spain;(30)Gastroenterology Department, Hospital Universitario Nuestra Sra. de la Candelaria, Santa Cruz de Tenerife, Spain;(31)Gastroenterology Department, Hospital del Mar and Institut Hospital del Mar d@E@Investigacions Mèdiques IMIM, Barcelona, Spain;(32)Gastroenterology Department, Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain;(33)Gastroenterology Department, Hospital Clínico San Carlos and Instituto de Investigación del Hospital Clínico San Carlos IdISSC, Madrid, Spain;(34)Gastroenterology Department, Hospital Universitario de Fuenlabrada, Madrid, Spain;(35)Gastroenterology Department, Hospital Dr. Josep Trueta, Girona, Spain;(36)Gastroenterology Department, Hospital General de Granollers, Barcelona, Spain;on behalf of the ENEIDA project of GETECCU *Co-senior authorship
P845: Vedolizumab induces endoscopic healing uniformly irrespective of disease location: post-hoc analysis of the LOVE-CD trialECCO'24Year: 2024
Authors: Hens, B.(1)*;Oldenburg, L.(2);Molnár, T.(3);Baert, F.(4);Clasquin, E.(2);Vermeire, S.(5);Löwenberg, M.(2);D@E@Haens, G.(2);
(1)University Hospital Brussels, Gastroenterology and Hepatology, Jette, Belgium;(2)Amsterdam University Medical Centers, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(3)Albert Szent-Györgyi Medical School, Gastroenterology and Hepatology, Szeged, Hungary;(4)AZ Delta, Gastroenterology and Hepatology, Roeselare, Belgium;(5)University Hospital Leuven, Gastroenterology and Hepatology, Leuven, Belgium;
P846: Impact of 5-ASA discontinuation in children with ulcerative colitis under biological therapyECCO'24Year: 2024
Authors: D@E@Arcangelo, G.(1)*;Di Bari, E.R.(1);Distante, M.(1);Rotulo, S.(1);Brecciaroli, M.(1);Catassi, G.(1);Aloi, M.(1);
(1)Sapienza University of Rome, Department of Pediatrics, Rome, Italy;
P847: Effectiveness of tofacitinib in ulcerative proctitis compared to left sided colitis and pancolitisECCO'24Year: 2024
Authors: SinghD.M., A.(1)*;Mahajan, R.(2);Midha, V.(3);Kaur, K.(4);Singh, D.(5);Bansal, N.(5);Sood, A.(2);
(1)Dayanand Medical College and Hospital- Ludhiana, Department of Gastroenterology, Ludhiana, India;(2)Dayanand Medical College and Hospital, Gastroenterology, Ludhiana, India;(3)Dayanand Medical College and Hospital, Medicine, Ludhiana, India;(4)Dayanand Medical College and Hospital, Pharmacology, Ludhiana, India;(5)Dayanand Medical College and Hospital, Research and Development, Ludhiana, India;
P848: Risankizumab Effectiveness in Ustekinumab-naïve and Ustekinumab-experienced Patients with Crohn’s Disease- Real-world Data from a Large Tertiary CenterECCO'24Year: 2024
Authors: Zinger, A.(1)*;Choi, D.(1);Choi, N.(1);Fear, E.(1);Fine , Z.(1);Cohen, R.D.(1);Dalal, S.D.(1);Krugliak Cleveland, N.(1);Pekow, J.(1);Rubin, D.T.(1);
(1)University of Chicago Medicine, Gastroenterology, chicago, United States;
P849: Bayesian network meta-analysis of the efficacy of advanced therapies for patients with moderately to severely active ulcerative colitis naïve to advanced therapyECCO'24Year: 2024
Authors: Jairath, V.(1)*;Leahy, T.P.(2);Potluri, R.(3);Wosik, K.(4);Gruben, D.(5);Cappelleri, J.C.(5);Bartolome, L.(6);
(1)Western University, Department of Medicine and Department of Epidemiology and Biostatistics, London- ON, Canada;(2)., Putnam Associates- LLC, Toronto- ON, Canada;(3)., Putnam Associates- LLC, New York- NY, United States;(4)., Pfizer Canada, Kirkland- QC, Canada;(5)., Pfizer Inc, Groton- CT, United States;(6)., Pfizer Inc, New York- NY, United States;
P850: Symptomatic effectiveness of ozanimod in routine clinical care of ulcerative colitis: an interim analysis of the multicentre, prospective, noninterventional COLIBRI studyECCO'24Year: 2024
Authors: Schubert, S.(1)*;Stein, J.(2);Efken, P.(3);Helwig, U.(4);Schulze, J.(5);Hellms, T.(6);Jorgensen, E.(7);Poehler, A.M.(8);Scheibner, F.(8);Makki, M.(8);Zeissig, S.(9);
(1)MVZ für Gastroenterologie am Bayerischen Platz, Gastroenterology, Berlin, Germany;(2)CED Studien UG, Gastroenterology, Frankfurt, Germany;(3)Gastroenterologische Gemeinschaftspraxis Minden, Gastroenterology, Minden, Germany;(4)Internistische Praxengemeinschaft Oldenburg, Internal Medicine and Gastroenterology, Oldenburg, Germany;(5)Praxisgemeinschaft Jerichow, Gastroenterology, Jerichow, Germany;(6)Department of Gastroenterology- Hepatology- Infectious Diseases and Endocrinology, Gastroenterology- Hepatology- Infectious Diseases and Endocrinology, Hannover, Germany;(7)Magen-Darm-Zentrum Remscheid, Gastroenterology, Remscheid, Germany;(8)Bristol Myers Squibb, n/a, Munich, Germany;(9)University Medical Center Dresden, Medicine I, Dresden, Germany;
P851: Therapeutic drug monitoring of infliximab and adalimumab versus clinical control during maintenance therapy in patients with Inflammatory Bowel DiseaseECCO'24Year: 2024
Authors: Muñoz Villafranca, M.D.C.(1)*;Merino , O.(2);Gómez , L.(2);Higuera, R.O.(1);Arreba , P.(1);Nagore, D.(3);Ruiz-Argüello, B.(3);Gorostiza, I.(4);López, M.L.(1);Ortiz de Zárate, J.(1);
(1)Hospital Universitario de Basurto, Gastroenterology, Bilbao, Spain;(2)Hospital Universitario de Cruces, Gastroenterology, Barakaldo, Spain;(3)Progenika Biopharma-Grifols, Biochemestry, Bilbao, Spain;(4)Hospital Universitario de Basurto, Research Unit, Bilbao, Spain;
P852: Metataxonomic and metabolomic profiling to predict response to anti-TNF therapy in Crohn’s DiseaseECCO'24Year: 2024
Authors: Foyzul, J.(1)*;Alexander, J.L.(1,2);Chappell, K.E.(1);Ibraheim, H.A.(1,2);Saifuddin, A.(1,3);Kennedy, N.A.(4,5);Bewshea, C.(4);Lin, S.(4,5);Hart, A.L.(3);Goodhand, J.R.(3,5);Ahmad, T.(4,5);Powell, N.(1,2);
(1)Imperial College London, Department of Metabolism- Digestion and Reproduction, London, United Kingdom;(2)Imperial College Healthcare NHS Trust, Department of Gastroenterology, London, United Kingdom;(3)St Marks Hospital and Academic Institute- Gastroenterology, Department of Gastroenterology, London, United Kingdom;(4)University of Exeter, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Exeter, United Kingdom;(5)Royal Devon University Healthcare NHS Foundation Trust, Department of Gastroenterology, Exeter, United Kingdom;UK Inflammatory Bowel Disease Pharmacogenetics Study Group
P853: Factors associated with intestinal tissue levels of anti-TNF in pediatric patients with Crohn@E@s DiseaseECCO'24Year: 2024
Authors: Dotlacil, V.(1)*;Coufal, S.(2);Lerchova, T.(3);Zarubova, K.(3);Kucerova, B.(1);Tlaskalova-Hogenova, H.(2);Kverka, M.(2);Bronsky, J.(3);Skaba, R.(1);Hradsky, O.(3);Rygl, M.(1);
(1)Charles University and Motol University Hospital, Department of Pediatric Surgery, Prague, Czech Republic;(2)Institute of Microbiology- Czech Academy of Sciences, Laboratory of Cellular and Molecular Immunology, Prague, Czech Republic;(3)Charles University and Motol University Hospital, Department of Pediatrics, Prague, Czech Republic;
P854: Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitisECCO'24Year: 2024
Authors: Khoo, E.(1,2)*;Amiss, A.(3);Ding, J.N.(4);Bryant, R.(5);Mohsen, W.(6);Connor, S.(7);Leung, R.(8);Croft, A.(9);Lynch, K.(10);Sparrow, M.(11);De Cruz, P.(12);An, Y.K.(1,2);Holtmann, G.(13);Begun, J.(1,2,3);
(1)Mater Hospital Brisbane, Department of Gastroenterology, South Brisbane, Australia;(2)The University of Queensland, Faculty of Medicine, St Lucia, Australia;(3)Mater Research, Inflammatory Bowel Disease, Woolloongabba, Australia;(4)St Vincent@E@s Hospital Melbourne, Department of Gastroenterology, Fitzroy, Australia;(5)The Queen Elizabeth Hospital, Department of Gastroenterology, Woodville South, Australia;(6)Gold Coast University Hospital, Department of Gasteroenterology, Southport, Australia;(7)Liverpool Hospital, Department of Gastroenterology, Liverpool, Australia;(8)Macquarie University Hospital, Department of Gastroenterology, Macquarie University, Australia;(9)Royal Brisbane and Women Hospital, Department of Gastroenterology, Herston, Australia;(10)Royal Adelaide Hospital, Department of Gastroenterology, Adelaide, Australia;(11)The Alfred, Department of Gastroenterology, Melbourne, Australia;(12)Austin Hospital, Department of Gastroenterology, Heidelberg, Australia;(13)Princess Alexandra Hospital, Department of Gastroenterology, Woolloongabba, Australia;
P855: Have biological agents changed the need for abdominal surgery in inflammatory bowel disease over time?ECCO'24Year: 2024
Authors: Suria, C.(1)*;Bosca-Watts, M.M.(1);García-Trueba, A.(2);Tosca, J.(1);Antón, C.(3);Sanahuja, A.(3);Merino, V.(3);Abril, C.(1);Ballester, M.P.(1);Romero, E.(1);Marti, D.(1);Galvez, C.(4);Ponce, M.(4);Pascual, I.(1);
(1)Clinic University Hospital of Valencia, Digestive Disease Department, Valencia, Spain;(2)University of Valencia, Digestive Disease Department, Valencia, Spain;(3)Clinic University Hospital of Valencia, Digestive Disease Deparment, Valencia, Spain;(4)Clinic University Hospital of Valencia, Endoscopy Department, Valencia, Spain;IBD Unit
P856: Influential factors on the clinical and radiological closure of resistant perianal fistula treated with stomaECCO'24Year: 2024
Authors: Candan , S.(1)*;Bakkaloglu , O.K.(2);Bayar , M.(3);Eskazan , T.(1);Hatemi , I.(4);Erzin , Y.(1);Celik , A.F.(1);
(1)Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty, Gastroenterology, Istanbul, Turkey;(2)KOŞUYOLU HIGH SPECIALIZATION EDUCATION AND RESEARCH HOSPITAL, Gastroenterology, istanbul, Turkey;(3)Istanbul Universit Cerrahpasa - Cerrahpasa Medical Faculty, Internal Medicine, Istanbul, Turkey;(4)Istnabul University Cerrahpasa - Cerrahpasa Medical Faculty, Gastroenterology, Istanbul, Turkey;
P857: Effectiveness and safety of subcutaneous infliximab in perianal Crohn@E@s disease: a multicentre cohort studyECCO'24Year: 2024
Authors: Andre, M.(1);Kirchgesner, J.(2);Laharie, D.(3);Guillo, L.(4);Abramowitz, L.(5);Seksik, P.(6);Nachury, M.(7);Fumery, M.(8);Amil, M.(9);Nancey, S.(10);Le Berre, C.(11);Moussata, D.(12);Buisson, A.(13);Fathallah, N.(14);Gilletta, C.(15);Uzzan, M.(16);Duveau, N.(17);Peyrin-Biroulet, L.(18);Nahon , S.(19);Savoye, G.(20);Charkaoui, M.(21);Vicaut, E.(22);Vuitton, L.(1)*;
(1)CHU Besançon, Department of Gastroenterology, Besançon, France;(2)APHP Saint Antoine, Gastroenterology, Paris, France;(3)CHU Bordeaux, Hepatogastroenterology, Bordeaux, France;(4)APHM Hopital Nord, Department of Gastroenterology, Marseille, France;(5)APHP Hopital Bichat, Department of Gastroenterology, Paris, France;(6)APHP Hopital Saint-Antoine, Department of Gastroenterology, Paris, France;(7)CHU Lille, Hepatogastroenterology, Lille, France;(8)CHU Amiens, Hepatogastroenterlogy, Amiens, France;(9)CH Vendée, Department of Gastroenterology, La Roche Sur Yon, France;(10)CHU Lyon Sud, Department of Gastroenterology, Lyon, France;(11)CHU Nantes, Department of Gastroenterology, Nantes, France;(12)CHU Tours, Department of Gastroenterology, Tours, France;(13)CHU Clermont-Ferrand, Department of Gastroenterology, Clermont-Ferrand, France;(14)Hopital Saint-Joseph, Department of Gastroenterology, Paris, France;(15)CHU Toulouse, Department of Gastroenterology, Toulouse, France;(16)APHP Hopital Mondor, Department of Gastroenterology, Créteil, France;(17)CH Roubaix, Department of Gastroenterology, Roubaix, France;(18)CHU Nancy, Department of Gastroenterology, Nancy, France;(19)CH Montfermeil, Department of Gastroenterology, Montfermeil, France;(20)CH Rouen, Department of Gastroenterology, Rouen, France;(21)CHU Dijon, Department of Gastroenterology, Dijon, France;(22)APHP, Methodology, Paris, France;
P858: Real World Outcomes of Dual Advanced Therapy in Inflammatory Bowel Disease in Children and Young AdultsECCO'24Year: 2024
Authors: Kellar, A.(1)*;Dolinger, M.(2);Spencer, E.(2);Dubinsky, M.(2);
(1)University of Chicago, Section of Pediatric Gastroenterology- Hepatology and Nutrition, Chicago, United States;(2)Icahn School of Medicine at Mount Sinai, Division of Pediatric Gastroenterology- Susan and Leonard Feinstein IBD Clinical Center, New York, United States;
P859: Sodium Butyrate supplementation significantly improved clinical outcomes and quality of life in patients with Crohn’s Disease – results from a randomized placebo-controlled studyECCO'24Year: 2024
Authors: Facchin PhD, S.(1);Calgaro , M.(2);Pandolfo , M.(2);De Barba , C.(1)*;Barberio , B.(1);Zingone , F.(1);Vitulo , N.(2);Savarino , E.V.(1);
(1)University of Padua, Surgical- Oncology and Gastroenterology, Padua, Italy;(2)University of Verona, Department of Biotechnology, Verona, Italy;
P860: Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis - a six-year follow-up studyECCO'24Year: 2024
Authors: Gros, B.(1,2)*;Ross, H.(1);Nwabueze, M.(1);Constantine-Cooke, N.(3,4);Derikx, L.A.(1,5,6);Lyons, M.(1);O@E@Hare, C.(1,7);Noble, C.(1);Arnott, I.D.(1);Jones, G.R.(1,8);Lees, C.W.(1,9);Plevris, N.(1);
(1)Western General Hospital, Edinburgh IBD Unit, Edinburgh, United Kingdom;(2)Reina Sofía University Hospital, Gastroenterology and Hepatology, Cordoba, Spain;(3)Western General Hospital, MRC Human Genetics Unit- Institute of Genetics and Cancer- University of Edinburgh, Edinburgh, United Kingdom;(4)Western General Hospital, Centre for Genomics and Experimental Medicine- Institute of Genetics and Cancer- University of Edinburgh, Edinburgh, United Kingdom;(5)Erasmus MC- University Medical Centre Rotterdam, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(6)Radboud University Medical Center, Inflammatory Bowel Disease Center- Department of Gastroenterology and Hepatology-, Nijmegen, The Netherlands;(7)Western General Hospital, Edinburgh Pharmacy Unit, Edinburgh, United Kingdom;(8)The Queen@E@s Medical Research Institute- University of Edinburgh, Centre for Inflammation Research, Edinburgh, United Kingdom;(9)Institute of Genetics and Cancer- University of Edinburgh- Western General Hospital, Centre for Genomics and Experimental Medicine, Edinburgh, United Kingdom;
P862: Effects of induction and maintenance therapy with risankizumab on health-related quality of life outcomes in patients with moderately to severely active ulcerative colitis: A post-hoc analysis of Phase 2b/3 trialsECCO'24Year: 2024
Authors: Panés, J.(1)*;Loftus Jr., E.V.(2);Armuzzi, A.(3);Siegmund, B.(4);Sands, B.E.(5);Boland, B.S.(6);Kalabic, J.(7);Lai, J.H.(8);Sharma, D.(7);Remple, V.(7);Sanchez Gonzalez, Y.(7);Lindsay, J.O.(9);
(1)Hospital Clínic Barcelona, IDIBAPS- CIBERehd, Barcelona, Spain;(2)Mayo Clinic College of Medicine and Science, none, Rochester, United States;(3)Humanitas University, Inflammatory Bowel Disease Center- IRCCS Humanitas Research Hospital, Milan, Italy;(4)Charité Universitätsmedizin Berlin, Medical Department- Division of Gastroenterology- Infectiology and Rheumatology, Berlin, Germany;(5)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States;(6)University of California- San Diego, Department of Medicine, San Diego, United States;(7)AbbVie Inc., none, North Chicago, United States;(8)AbbVie Inc.and Health Outcomes Division- College of Pharmacy- The University of Texas at Austin, none, Austin, United States;(9)Barts Health NHS Trust, Department of Gastroenterology, London, United Kingdom;
P863: Prospective outcome following ustekinumab treatment in a real-world cohort of inflammatory bowel disease patients.ECCO'24Year: 2024
Authors: Ramos Lopez, L.(1)*;Ramos-Díaz, R.(2);Benítez-Zafra, F.(3);Morant-Domínguez, A.(3);Vera-Santana , B.(3);Mourani-Padrón, I.(4);Alonso-Abreu, I.(5);Carrillo-Palau, M.(5);Reygosa , C.(5);Medina-Chico , J.S.(6);Gutierrez-Nicolás, F.(7);Nazco-Casariego, J.(7);Hernández-Guerra, M.(3);
(1)Hospital Universitario De Canarias, IBD Unit. Gastroenterology Department, Santa Cruz De Tenerife, Spain;(2)Hospital Universitario de Canarias, Reasearch Unit Fundación Canaria Instituto de Investigación Sanitaria de Canarias FIISC- La Laguna- Spain., La Laguna, Spain;(3)Hospital Universitario de Canarias, Gastroenterology Department, La Laguna, Spain;(4)Hospital Universitario de Canarias, Research Unit Fundación Canaria Instituto de Investigación Sanitaria de Canarias FIISC- La Laguna- Spain., La Laguna, Spain;(5)Hospital Universitario de Canarias, IBD Unit. Gastroenterology Department, La Laguna, Spain;(6)Hospital Universitario de Canarias, Specialist Nurse.IBD Unit. Gastroenterology Department, La Laguna, Spain;(7)Hospital Universitario de Canarias, Hospital Pharmacy Department, La Laguna, Spain;
P864: The Effect of Ustekinumab on Mucosal Inflammation in Paediatric Crohn’s Disease: The REALITI Real-World Evidence Effectiveness StudyECCO'24Year: 2024
Authors: Adler, J.(1);Steiner, S.(2)*;Saeed, S.(3);Colletti, R.(4);Strauss, R.(5);Godwin, B.(6);Sheahan, A.(7);Zhang, R.(7);Kim, L.(8);Xiao, Y.(9);Volger, S.(5);
(1)University of Michigan, C.S. Mott Children@E@s Hospital- Michigan Medicine, Ann Arbor- MI, United States;(2)Indiana University Health, Riley Hospital for Children, Carmel- IN, United States;(3)Wright State University, Dayton Children’s Hospital, Dayton- OH, United States;(4)University of Vermont, Children@E@s Hospital, Burlington- VT, United States;(5)Janssen Research & Development- LLC, Pediatric Development Team, Spring House- PA, United States;(6)Janssen Research & Development- LLC, Pediatric Development Team-, Spring House- PA, United States;(7)Janssen Research & Development- LLC, Immunology Epidemiology, Titusville- NJ, United States;(8)Janssen Research & Development- LLC, Statistics and Decision Sciences, Spring House- PA, United States;(9)Cytel, n/a, Waltham- MA, United States;